Bristol-Myers Squibb says its cancer drug ixabepilone has demonstrated activity in a Phase II trial for metastatic breast cancer among patients resistant to three types of chemotherapy. The trial involved 126 patients in a single-arm study.
"Drug resistance is a major concern in treating patients with advanced disease," said Renzo Canetta, vice president, Oncology Global Clinical Research, Bristol-Myers Squibb. "The results of this study are important as they provide valuable information about this investigational compound and its potential in patients with advanced breast cancer that is no longer responding to any of the current U.S. approved chemotherapy treatments."
- here's the release [1]
ALSO: BMS has scrubbed a partnership with Medivir to develop MIV-170 for HIV. Medivir said the drug did not meet BMS' desired profile. Release [2]
Related Articles:
Better times ahead for BMS? Report [3]
BMS unveils positive diabetes data. Report [4]
Patent victory reignites rumors of BMS takeover. Report [5]
Probation draws to a close for Bristol-Myers. Report [6]
Links:
[1] http://www.fiercebiotech.com/node/7525
[2] http://www.fiercebiotech.com/node/7527
[3] http://www.fiercebiotech.com/story/spotlight-better-times-ahead-for-bms/2007-04-23
[4] http://www.fiercebiotech.com/story/bms-unveils-positive-diabetes-data/2007-06-25
[5] http://www.fiercebiotech.com/story/patent-victory-reignites-rumors-of-bms-takeover/2007-06-20
[6] http://www.fiercebiotech.com/story/probation-draws-to-a-close-for-bristol-myers/2007-06-15